Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Marietta Rheumatology Associates
mi
from
Marietta, GA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Marietta Rheumatology Associates
mi
from
Marietta, GA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis and Rheumatology Consultants, P.A.
mi
from
Edina, MN
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis and Rheumatology Consultants, P.A.
mi
from
Edina, MN
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center PRIME
mi
from
Lake Success, NY
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center PRIME
mi
from
Lake Success, NY
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Low Country Rheumatology, PA
mi
from
North Charleston, SC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Low Country Rheumatology, PA
mi
from
North Charleston, SC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Sentara Medical Group, Clinical Research
mi
from
Norfolk, VA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Sentara Medical Group, Clinical Research
mi
from
Norfolk, VA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
IMEDICA s.r.o.
mi
from
Brno,
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
IMEDICA s.r.o.
mi
from
Brno,
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated:  12/31/1969
UF Health
mi
from
Gainesville, FL
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated: 12/31/1969
UF Health
mi
from
Gainesville, FL
Click here to add this to my saved trials
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated:  12/31/1969
Florida Surgical Center
mi
from
Gainesville, FL
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated: 12/31/1969
Florida Surgical Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anniston, AL
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami Lakes, FL
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Debary, FL
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
South Miami, FL
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesquite, TX
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Bialystok,
A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Bialystok,
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
mi
from
Colorado Springs, CO
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of CT/NY
mi
from
Danbury, CT
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of CT/NY
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Sarasota Arthritis Center
mi
from
Sarasota, FL
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Sarasota Arthritis Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Institute of Arthritis Research
mi
from
Idaho Falls, ID
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Institute of Arthritis Research
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Cumberland, MD
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Hagerstown, MD
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Carolina Arthritis Associates
mi
from
Wilmington, NC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Carolina Arthritis Associates
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 032001
mi
from
Capital Federal,
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 032001
mi
from
Capital Federal,
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Care Access Research - Huntington Beach
mi
from
Huntington Beach, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Care Access Research - Huntington Beach
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Rheumatology Center of San Diego
mi
from
Escondido, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Rheumatology Center of San Diego
mi
from
Escondido, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Marietta Rheumatology
mi
from
Marietta, GA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Marietta Rheumatology
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
mi
from
Columbia, SC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
Click here to add this to my saved trials